Focused on the Fundamentals of Patient Impact

Frazier Life Sciences invests globally in companies discovering, developing, and commercializing novel therapeutics at all stages of development.

View Drug Approvals

How We Invest

Our funds comprise both private-focused vehicles (Venture Funds) and public-focused vehicles (Public Funds) that enable us to invest across the spectrum of companies developing novel therapeutics. Across all opportunities, we take a collaborative, team-based approach to perform deep technical diligence that leverages the experience of our firm and team.

View Company View Company View Company

Venture Funds

Our Venture Funds primarily invest in private companies, focusing on company creation (over 30 companies formed since 2005) and Series A & B companies. We form true partnerships with distinctive entrepreneurs to build world-class companies and accelerate advancement of new therapeutic options for patients. Our latest Venture Fund is Frazier Life Sciences XI, a $987 million fund that was raised in 2022.

FEATURED COMPANY
lengo logo

Lengo was a Frazier-founded company, with the idea that there was an opportunity to discover and develop a CNS-penetrant inhibitor of EGFR Exon 20 insertions for NSCLC. The Frazier team structured a collaborative partnership with Jubilant Biosys, and led Lengo’s Series A as the only institutional investor in the round. Many Frazier team members played critical roles in the company, and Lengo was ultimately acquired by Blueprint Medicines in 2021 for $250M upfront and $225M in additional milestones.

Lengo Therapeutics

View Company
amunix logo

Frazier acquired a majority stake in Amunix in 2018, and played a critical role in building the management team and re-focusing the portfolio towards conditionally-active bispecific antibodies. The Amunix team made rapid progress in advancing several programs through preclinical studies, leading to acquisition by Sanofi for $1B upfront and $225M in additional milestones.

Amunix Pharmaceuticals

View Company
acerta logo

Frazier participated in Acerta’s Series A, to advance the company’s preclinical second generation BTK inhibitor (acalabrutinib). Frazier’s investment was made possible through relationships formed at Calistoga Pharmaceuticals, a Frazier-founded company. Upon entering clinical trials, acalabrutinib showed substantial efficacy in patients with multiple forms of hematologic malignancies, leading to acquisition by Astrazeneca in 2015 for $4B upfront and $3B in milestone payments.

Acerta Pharma

View Company
View Company View Company View Company

Public Funds

Our Public Funds provide capital to small- and mid-cap public biotech companies in financings, including follow-ons including CMPOs, PIPEs, IPOs, as well as supporting our companies in the open market. We partner with our public portfolio companies much as we do with our private portfolio companies. The Public Funds are investing over $1 billion of committed capital.

FEATURED COMPANY
krystal logo

Frazier was the sole investor in a proprietary PIPE financing before Phase 1 clinical data. Frazier also helped the company recruit a new board member and expand its banking and analyst relationships. Following FDA approval of Vyjuvek, Frazier participated in a $160MM private placement financing to support Vyjuvek’ s commercial launch.

Krystal Biotech

View Company
sierra oncology logo

Frazier initially invested in Sierra Oncology before the company went public. Sierra later acquired momelotinib from Gilead, and Frazier co-led a financing to license AZD5153 from AstraZeneca and continued to invest in the company after positive Phase 3 data for momelotinib.

Sierra Oncology

View Company
chinook logo

Frazier Public Fund’s first investment was in Chinook, and Frazier continued to build its position through multiple financings to support the development of Atrasentan and BION-1301 for IgA nephropathy. Frazier also co-led a spinout of Chinook into a new private company, SanReno Therapeutics.

Chinook Therapeutics

View Company

Our Values

Since 1991, the Frazier Life Sciences team has actively partnered with exceptional entrepreneurs to develop novel and impactful therapies for patients. Underlying these efforts are a set of core values that guide how we invest, advise, and operate as a firm.

Integrity Icon

Integrity

We choose the harder right over the easier wrong in serving the interests of patients, portfolio companies, and other stakeholders in the healthcare ecosystem.

Empowerment Icon

Empowerment

We invest in each other (early, often, and thoughtfully) and take ownership in a collaborative, compassionate, and respectful manner to achieve firm goals.

Perseverance Icon

Perseverance

We advance patient care with determination and purpose to positively impact our community.

Transparency Icon

Transparency

We promote constructively candid and respectful dialogue to get to the right answers.

Social Impact Icon

Social Impact

We work to effect positive change in the areas of diversity, equity, inclusion, accessibility, and the environment.

Performance Icon

Performance

We seek to deliver attractive results and improved outcomes for everyone we serve.

Selected Drug Approvals From Our Portfolio

andexxa logo

Portola Pharmaceuticals

bevyxxa logo

Portola Pharmaceuticals

calquence logo

Acerta Pharma

epaned logo

Silvergate Pharmaceuticals

galafold logo

Amicus Therapeutics

horizant logo

XenoPort

ionsys logo

Incline Therapeutics

jemperli logo

AnaptysBio

katerzia logo

Silvergate Pharmaceuticals

livmarli logo

Mirum Pharmaceuticals

minocin logo

Rempex Pharmaceuticals

ofirmev logo

Cadence Pharmaceuticals

osphena logo

QuatRx Pharmaceuticals

qbrelis logo

Silvergate Pharmaceuticals

relizorb logo

Alcresta Therapeutics

rezzayo logo

Cidara Therapeutics

rozlytrek logo

Ignyta

rubraca logo

Clovis Oncology

solesta logo

Oceana Therapeutics

teflaro logo

Cerexa Pharmaceuticals

tembexa logo

Chimerix

vabomere logo

Rempex Pharmaceuticals

ventavis logo

CoTherix

voquezna dual logo

Phathom Pharmaceuticals

voquezna triple logo

Phathom Pharmaceuticals

vyjuvek logo

Krystal Biotech

xacduro logo

Entasis Therapeutics

xatmep logo

Silvergate Pharmaceuticals

xenleta logo

Nabriva Therapeutics

xtampza logo

Collegium Pharmaceuticals

zerbaxa logo

Calixa Therapeutics

zoryve logo

Arcutis Biotherapeutics

zydelig logo

Calistoga Pharmaceuticals

References to specific portfolio companies are presented for illustrative purposes only and should not be considered as being generally representative of all portfolio companies of any particular strategy or fund. For a complete list of all portfolio companies, please see the Portfolio page.

times icon menu bg caret up